TC Biopharm (Holdings) Plc (TCBPY)
OTCMKTS · Delayed Price · Currency is USD
0.0055
+0.0054 (5,400.00%)
Inactive · Last trade price on Apr 1, 2026
TC Biopharm (Holdings) Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
39
Market Cap
11.57K USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.84M | 1.87M | 94.30% |
| Dec 31, 2021 | 1.98M | - | - |
| Dec 31, 2020 | 1.98M | -1.45M | -42.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTC Biopharm (Holdings) News
- 1 year ago - TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient - PRNewsWire
- 1 year ago - TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells - PRNewsWire
- 1 year ago - TCBP Announces Transition from Nasdaq to OTC Markets - PRNewsWire
- 1 year ago - TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead - PRNewsWire
- 1 year ago - TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company - PRNewsWire
- 1 year ago - TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum - PRNewsWire
- 1 year ago - TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial - PRNewsWire
- 1 year ago - TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial - PRNewsWire